On-Demand Webinar: Accelerating Antibody Characterization through Flow Cytometry
Antibody characterization is an essential part of the biopharmaceutical development process. It is needed to differentiate among biologics/biosimilars, to help screen monoclonal antibody (mAb) drug candidates, to optimize production processes, and to satisfy regulatory requirements.
Several techniques may be used to determine the class and subclass of the antibody, including Western and dot blotting, ELISA, radioimmunoassay, mass spectrometry, surface plasmon resonance, and flow cytometry.
During this webinar, the speakers will discuss how flow cytometry has progressed antibody characterization and how this method is used within their respective research fields.
Key Webinar Discussion Topics Include:
- Discussion on the importance of therapeutic antibodies, the challenges of their isolation, and the future of the field
- General background on the importance of, and methods for, antibody characterization, with an emphasis on flow cytometry
- An overview of the spectrum in antibody characterization tools, and highlights of the benefits of advanced flow cytometry
- An outline of the differences of traditional flow vs. advanced flow cytometry for antibody characterization
Katja Hanack, Ph.D.
University of Potsdam, Potsdam, Germany
Dr. Hanack received her Ph.D. in biomaterial sciences in 2006 from the University of Potsdam, Germany, where she has been the Endowed Chair of Immunotechnology since 2015. Her laboratory works on improving technologies for antibody production, including the creation of monoclonal antibodies through hybridomas via the use of transgenic fusion cell lines, use of virus-like particles to create an antibody response, and generation of camelid monoclonal antibodies and nanobodies. She is also founder of the custom monoclonal antibody company new/era/mabs GmbH.
Will Howat, Ph.D.
Abcam, Cambridge, United Kingdom
Dr. Howat is Abcam’s senior director of validation and technical quality. Prior to joining Abcam in 2018, he worked at AstraZeneca as team leader of its molecular pathology group, where his team developed biomarker assays for preclinical, phase 1, and phase 2 clinical trials. Before that he was at Cancer Research UK’s Cambridge Institute, where he set up and ran the Histopathology/ISH core facility for 9 years. He has also worked at the Wellcome Sanger Institute on the Atlas of Protein Expression and was responsible for R&D within the immunohistochemistry group. Dr. Howat received his Ph.D. in pathology from the University of Southampton. His publications span key journals such as The Lancet, Nature, Science, Nature Genetics, The American Journal of Pathology, and The Journal of Pathology.
Nina Senutovitch, Ph.D.
Sartorius, Albuquerque, NM, United States
Dr. Senutovitch received her B.Sc. in biochemistry from New Mexico State University. She completed her Ph.D. in biological sciences at Carnegie Mellon University, where she developed and detailed the function of novel fluorescent probes. As a postdoctoral fellow at the University of Pittsburgh, she established biosensor-based live-cell screening assays for the detection of hepatotoxicity, including the use of a human liver “organ-on-a-chip” model. She joined Sartorius in 2019 as a senior scientist in Cell Analytics.